Back to Blog August 29, 2017 in

John McIlwraith, Allos Ventures

Navigate all the resources featured in the Landscape Guide by geographic location, industry sector, and organization type. Landscape Guide
Everything you need to know to make a meaningful first connection can be found in our 2021-22 Landscape Guide! Download the Guide

2023 MVCA Research Report

Our state's entrepreneurial economy hinges on our ability to provide capital to our high-growth, high-potential companies. Download the Report

John co-founded Allos in 2010, but he did some pretty cool stuff before that, too. He was also a lawyer.

John started his career as a corporate lawyer at Jones Day, where he co-founded the Private Ventures Group after determining that the firm needed a better way to serve the needs of early-stage companies and venture capital/private equity investors. After several years of representing VC firms, like Primus and Morgenthaler, and early-stage technology companies, he decided he was envious of how much fun his clients were having, and that he wanted to go down a more entrepreneurial path.

Although he achieved success as an attorney, he knew that to succeed as a venture capitalist he would need operating experience. So, he joined publicly-traded Quantum Health Resources, a provider of drugs and related therapies to patients with rare, chronic diseases, as SVP of business development and general counsel. While there, he was able to gain insights into the healthcare industry, including through being involved in the launch of a mail-order specialty pharmacy and several new products. In 1997, after Quantum was sold to Olsten Health Services, where John continued on as SVP of business development, he was recruited by Blue Chip Venture Company to join the firm as its third partner.

John’s investment experience includes software, business services, and healthcare companies, such as Assurex Health (sold to Myriad Genetics), Bluegill Technologies (sold to Checkfree), Blue Chip Surgical (sold to NueHealth), Inspiris (sold to United Healthcare), Medhost (sold to HealthTech Holdings), Healthscribe (sold to Spheris), and Renal Solutions (sold to Fresenius). He is still a managing director with Blue Chip, and is responsible for its investments in Endocyte and Nine Sigma. He is also active with Blue Chip’s Validation Fund, which invested in seed-stage technology companies in Ohio.

John has been involved in a variety of early-stage venture initiatives throughout the region. He was active in the formation of Gazelle TechVentures, where he served on the executive and investment committees, and where he met Don. He was also a founding member of the Michigan Venture Capital Association board of directors, and was the founding chairman of VentureOhio. And he is a founding board member at OCEAN Accelerator.